Is NextCure, Inc. (NXTC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.7% / 30% | 158.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 13.7% / 33% | 158.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 7.4% / 33% | 84.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 13.7% / 33% | 158.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 7.4% / 33% | 84.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -111.2% | |
| Return on Assets (ROA) | -55.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$50M |
| Free Cash Flow | -$50M |
| Total Debt | $5M |
| Debt-to-Equity | 14.7 |
| Current Ratio | 4.1 |
| Total Assets | $50M |
Price & Trading
| Last Close | $10.13 |
| 50-Day MA | $12.08 |
| 200-Day MA | $9.01 |
| Avg Volume | 35K |
| Beta | 1.6 |
|
52-Week Range
$2.69
| |
About NextCure, Inc. (NXTC)
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NextCure, Inc. (NXTC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NextCure, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NextCure, Inc.'s debt ratio?
NextCure, Inc.'s debt ratio is 13.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.4%.
What are NextCure, Inc.'s key financial metrics?
NextCure, Inc. has a market capitalization of $36M. Return on equity stands at -111.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.